An Adverse Event Is Not Always Obvious: A Practical Guide for Australian Listed Medicine Sponsors

For sponsors of listed medicines, pharmacovigilance does not begin when a report reaches the PV team. It begins when someone, somewhere in the organisation, first receives information about a possible adverse reaction.

That information might come through a customer complaint, an email to the sales team, a social media comment, a distributor or a conversation with a healthcare professional. It may not look like a conventional adverse event report, and the person receiving it may not realise that it requires further assessment.

This is where gaps in a sponsor’s pharmacovigilance system can emerge.

For Australian sponsors of listed medicines, including complementary medicines and supplements, having a process for collecting and managing safety information is essential. The challenge is ensuring that relevant information is recognised, documented and escalated, regardless of where it originates.

Read More

Common PV Mistakes Made by Supplement Companies with Products Listed on the ARTG

For many supplement companies, pharmacovigilance is not the first regulatory priority that comes to mind.

The focus is often on getting a product listed on the Australian Register of Therapeutic Goods (ARTG), maintaining manufacturing compliance, managing claims, and ensuring that labels meet regulatory requirements. Once the product is on the market, however, sponsors continue to have important responsibilities for monitoring and managing product safety.

This is where smaller supplement companies can sometimes find themselves exposed.

A product being a listed medicine does not mean that pharmacovigilance can be treated as a formality. Sponsors remain responsible for having appropriate systems in place to identify, assess, document, and report adverse events associated with their products.

Read More